â† Research library / Growth hormone axis

Tesamorelin: What the Evidence Actually Shows

Grade A, human RCT evidence FDA-approved (specific indication)

The short version

A GHRH analog, FDA-approved as Egrifta for excess visceral fat in HIV-associated lipodystrophy.
Three randomized controlled trials totaling 870 participants.
Produces 15-18% reduction in visceral adipose tissue over 26 weeks, and the effect is visceral-selective, subcutaneous fat is largely unaffected.
The limitation that matters: visceral fat re-accumulates within 6-12 weeks of stopping.
Any use outside the approved HIV-lipodystrophy indication is off-label.

Why this page matters

Tesamorelin has the strongest human evidence base of any compound commonly discussed in this category. Most peptides marketed for body composition rest on animal data or mechanism. This one has pivotal trials, an FDA approval, and an independent health technology assessment. If you want to know what a Grade A peptide actually looks like, this is it.

What it is

A synthetic analog of growth hormone-releasing hormone, stabilized against enzymatic degradation so it survives longer than native GHRH. Like sermorelin, it signals the pituitary rather than supplying growth hormone directly, but with different pharmacokinetics and a substantially larger body of outcome data.

What the research shows

The evidence base is three RCTs, each comparing 2 mg daily subcutaneous tesamorelin against placebo:^[1]

Trial	N	Design
LIPO-010	412	26-week main phase + 26-week extension
CTR-1011	404	26-week main phase + 26-week extension
Stanley et al. 2014	54	Measured liver fat alongside VAT

Findings across the program:

15-18% reduction in visceral adipose tissue at 26 weeks.^[1]
Visceral-selective, subcutaneous fat was largely unaffected. This is unusual and clinically meaningful, since visceral fat carries the metabolic risk.
The 2014 JAMA trial found significant reductions in both visceral fat and liver fat.^[1]
More recent work has reported VAT and liver fat reductions in INSTI-treated people with HIV.^[3]

The limitation the marketing leaves out

Discontinuation studies confirm that visceral fat begins to re-accumulate within 6-12 weeks of stopping treatment.^[1] The effect is real, well-measured, and maintenance-dependent. This is not a course of treatment that produces a durable result you keep. It is an ongoing therapy, and you should understand that before you start rather than after you stop.

The independent clinical review also characterized the effects as modest and not sustained on discontinuation. We'd rather quote that than bury it.

Who it may suit

Adults whose primary concern is visceral rather than subcutaneous adiposity
People with metabolic risk markers where visceral fat is the clinically relevant target
People prepared for a genuinely long program, the trial endpoints are at 26 weeks
People who understand this is maintenance therapy, not a one-time intervention

Who should not use this

Active malignancy, contraindicated
Any cancer history, requires oncologist involvement
Pregnancy or breastfeeding
Disruption of the hypothalamic-pituitary axis, pituitary surgery, radiation, tumor, or trauma
Active proliferative retinopathy or uncontrolled diabetes
Known hypersensitivity to tesamorelin or mannitol

What this will not do

It will not reduce subcutaneous fat, that's the visible layer. Visceral-selective means what it says, and it surprises people.
It will not hold the result after you stop. 6-12 weeks to re-accumulation.
It will not work on a short program. The primary endpoints are at 26 weeks. An 8-week run measures nothing here.
It will not replace metabolic care, diet, training, and glycemic management remain the base.

Side effects

From the trial program: injection site reactions (common), arthralgia, myalgia, peripheral edema, paresthesia, nausea, and rash. Effects on glucose tolerance and insulin sensitivity are the ones requiring monitoring, this is a GH-axis therapy and glucose monitoring is standard, particularly in anyone with prediabetes or diabetes.

See the full FDA prescribing information for the complete profile.

Regulatory status

FDA-approved as Egrifta for the reduction of excess abdominal fat in people with HIV-associated lipodystrophy. That is the approved indication, the only one.

Any other use is off-label. Off-label prescribing is legal and common in medicine, but it means the safety and efficacy data supporting your use has not been reviewed by FDA for that purpose. Tesamorelin is also under patent as a branded product.

Common questions

Why was it studied in HIV patients?

HIV-associated lipodystrophy produces a distinctive pattern of visceral fat accumulation, which made it a clean population for measuring a visceral-selective effect. That's also why generalizing the results to other populations requires care, the trial participants aren't necessarily like you.

How is it different from sermorelin?

Same mechanism class, very different evidence. Tesamorelin has pivotal RCTs and an FDA approval for a specific indication; sermorelin has a smaller adult outcome literature. Different pharmacokinetics and different cost.

What happens if I stop?

Visceral fat begins re-accumulating within 6-12 weeks. Plan for this being ongoing, or plan for the result being temporary.

References

Clinical Review Report: Tesamorelin (Egrifta). CADTH. NCBI Bookshelf NBK539136
EGRIFTA (tesamorelin for injection) prescribing information. FDA. Link
Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV. PMC10678288

See if this fits your goals